7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,681.27

+639.88

+0.83%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCQB - Delayed Quote USD

CytoDyn Inc. (CYDY)

0.2200 -0.0100 (-4.35%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for CYDY

Chart Range Bar

Interval:

In partnership with ChartIQ

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

CytoDyn to Host Investor Webcast

CytoDyn to Host Investor Webcast

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer

CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

CytoDyn to Present at the LD Micro Invitational XVI

CytoDyn to Present at the LD Micro Invitational XVI

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

CytoDyn to Host Investor Webcast

CytoDyn to Host Investor Webcast

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: